Last updated: September 24, 2026
Digoxin immune fab (ovine), marketed primarily as DigiFab, is a niche hospital antidote for life-threatening digoxin toxicity and selected poisonings from related cardiac glycosides. Its market is defined by low-volume, high-urgency demand, limited clinical substitution, hospital formulary stocking, and concentrated supply. Public sources do not disclose standalone DigiFab revenue, unit sales, or product-level margins. The commercial outlook therefore depends more on pricing, availability, regulatory continuity, and hospital stocking than on conventional prescription-volume growth.
What is the FDA status of digoxin immune fab (ovine)?
DigiFab is an FDA-approved biological product containing ovine-derived digoxin-specific antibody Fab fragments. It binds digoxin and related cardiac glycosides, allowing the complexes to be cleared from circulation. The product is administered intravenously for potentially life-threatening or life-threatening digoxin toxicity.
| Item |
Data |
| Active ingredient |
Digoxin immune Fab (ovine) |
| Dosage form |
Intravenous injection |
| Manufacturer historically associated with product |
BTG Specialty Pharmaceuticals |
| Current corporate ownership context |
BTG was acquired by SERB Pharmaceuticals in 2020 |
| Primary indication |
Life-threatening or potentially life-threatening digoxin toxicity |
| FDA product category |
Biological antidote |
| Administration |
Intravenous |
| Main institutional customers |
Hospitals, emergency departments, intensive-care units, poison centers and emergency-stock programs |
| Principal alternative |
Digibind, a legacy digoxin immune Fab product |
| Biosimilar competition |
No FDA-approved biosimilar or interchangeable product identified in the cited public sources |
The FDA-approved label describes DigiFab as an ovine antibody fragment preparation that binds digoxin and related molecules. Treatment decisions depend on serum digoxin concentration, estimated body burden, clinical status, renal function and the timing of exposure. [1]
When did DigiFab receive FDA approval and lose exclusivity?
DigiFab was approved in 2001, well before the modern biosimilar framework under the Biologics Price Competition and Innovation Act. Its initial market protection is no longer the principal commercial barrier.
The relevant exclusivity picture is:
| Protection type |
Commercial significance |
| FDA approval |
Remains the primary regulatory basis for marketing |
| Orphan-drug exclusivity |
Any original approval-linked period has expired |
| Biologic reference-product exclusivity |
The product predates the modern BPCIA reference-product framework |
| Patent exclusivity |
No widely cited, currently blocking DigiFab patent estate is evident in standard public drug-patent sources |
| Manufacturing know-how |
Potentially more important than expired or absent composition patents |
| Hospital stocking position |
A practical commercial barrier because clinicians need immediate access |
DigiFab should be analyzed as a mature biologic antidote rather than as a product with meaningful remaining regulatory exclusivity. The absence of a visible blocking patent does not eliminate entry barriers. Producing a consistent ovine antibody fragment, validating potency, controlling immunogenicity, establishing source-animal controls and obtaining an FDA-compliant manufacturing process can require substantial investment.
What patents protect digoxin immune Fab (ovine)?
No current, high-value patent blocking entry for the active ingredient is readily identifiable from the principal public sources used for drug-patent analysis. The relevant intellectual-property risk is more likely to involve process, purification, formulation, analytical testing, source-animal controls and manufacturing documentation than a broad composition-of-matter claim.
Patent-estate assessment
| Patent category |
Assessment |
| Composition of matter |
Likely expired or commercially weak for the mature product |
| Antibody sequence or binding claims |
Potentially relevant only if tied to a specific proprietary antibody population or engineered construct |
| Manufacturing process |
Could protect fermentation, immunization, purification, viral clearance or potency-control steps |
| Formulation |
Could cover stability, concentration, excipients or container closure, although a blocking claim has not been established here |
| Method of use |
Broad use in digoxin toxicity is unlikely to provide durable exclusivity for a long-approved antidote |
| Trade secrets |
Likely important in process control and batch reproducibility |
| Regulatory know-how |
Material for a replacement product because the therapy is a biological antidote with narrow clinical-use data |
The product’s strongest practical protection is likely manufacturing complexity combined with low expected market volume. A potential entrant must justify a development program for a product used primarily when a rare, severe event occurs. That makes the economic return less predictable than for a chronic medicine.
How large is the digoxin immune Fab market?
The market is small in patient volume but strategically important to hospitals. Demand is linked to exposure events rather than chronic treatment prevalence.
Demand drivers
- Digoxin prescriptions and the installed population of patients using digoxin.
- Accidental or intentional overdose.
- Renal impairment, which can increase digoxin exposure and prolong toxicity.
- Poisoning by cardiac glycoside-containing plants, including oleander and foxglove-related exposures.
- Hospital requirements for immediate access to antidotes.
- Poison-center protocols and emergency preparedness.
- Product shortages or allocation policies that prompt hospitals to hold larger inventories.
Demand constraints
- Declining use of digoxin in several cardiovascular settings.
- Improved prescribing and therapeutic-drug monitoring.
- Limited annual poisoning volume relative to mainstream emergency medicines.
- High acquisition cost, which encourages strict stocking controls.
- Expiration and inventory-carrying costs for hospitals.
- Lack of recurring outpatient use.
Digoxin immune Fab is therefore an availability-sensitive product. Hospitals may purchase it even when annual utilization is low because delayed treatment can create substantial clinical and liability risk.
What is the financial trajectory for DigiFab?
Standalone revenue and profit data are not publicly reported. BTG historically disclosed specialty-pharmaceutical results at a segment or portfolio level rather than publishing a separate DigiFab income statement. SERB is privately held and does not provide the same level of public product-level financial reporting as a listed company.
The likely financial trajectory has four phases:
| Period |
Financial profile |
| Early commercialization |
Specialist antidote adoption, formulary placement and establishment of hospital stocking |
| Mature market |
Stable but low-volume demand, supported by emergency-use pricing and limited direct competition |
| Portfolio ownership transition |
Product value incorporated into BTG’s specialty-pharmaceutical portfolio and later SERB’s hospital and critical-care strategy |
| Current phase |
Revenue likely depends on price, supply continuity, inventory contracts and geographic expansion rather than prescription growth |
The key economic variable is net price per treated patient or stocked treatment course, not prescription volume. A hospital may need multiple vials for a single severe overdose, allowing a small number of cases to generate material order value. At the same time, annual revenue remains exposed to random event frequency and hospital inventory decisions.
Revenue sensitivity
A simplified commercial model is:
Revenue = treated cases x average vials per case x net price per vial
That model is incomplete because hospitals also buy for emergency inventory. A better model includes stocked but unused product:
Revenue = treatment utilization + replacement of expiring inventory + emergency-stock contracts
The principal upside is price realization and supply reliability. The principal downside is a reduction in digoxin use, fewer severe exposures, competitive entry, or hospital efforts to limit inventory expense.
What is the Orange Book status of digoxin immune Fab?
DigiFab is a biologic product, not a conventional small-molecule drug. The Orange Book is therefore not the principal reference for its approval, patent and exclusivity status. Biologic products are generally evaluated through FDA biologics databases and the Purple Book framework, depending on the product’s regulatory history.
No current Orange Book-style patent listing should be assumed to protect DigiFab against a competing biological antidote. The absence of a conventional Orange Book listing does not mean that a competitor could launch immediately. A competing product would still need FDA approval, manufacturing validation, clinical and analytical comparability data, pharmacovigilance systems and reliable commercial supply.
Are there Paragraph IV challenges to DigiFab?
No material Paragraph IV litigation involving DigiFab is identified in the cited public sources. Paragraph IV certification is principally associated with abbreviated new drug applications for small-molecule products under the Hatch-Waxman framework. A competing digoxin immune Fab product would more likely follow a biologics pathway than a conventional ANDA pathway.
Why a standard generic launch is unlikely
A chemically identical generic cannot replicate an ovine antibody-fragment product in the same manner as a small molecule. An entrant would need to demonstrate that its product is sufficiently characterized, consistently manufactured and clinically appropriate for the intended use. The regulatory pathway would depend on the product’s legal classification and reference-product status.
Potential regulatory routes could include:
- A biologics license application for a new biological product.
- A biosimilar pathway if an appropriate reference-product framework applies.
- A full or abbreviated pathway based on FDA classification and product-specific precedent.
There is no identified FDA-approved biosimilar or interchangeable product for digoxin immune Fab (ovine) in the cited sources.
Which companies are challenging or competing with DigiFab?
Direct competition is limited. The principal historical competitor is Digibind, another digoxin immune Fab product. Digibind was associated with GlaxoSmithKline and later other portfolio arrangements, while DigiFab was associated with BTG. Product availability and commercial status have changed over time, and current competition should be assessed by market rather than by historical brand recognition.
| Competitor type |
Competitive threat |
| Digibind or successor supply |
Direct product competition where commercially available |
| New ovine Fab manufacturer |
High regulatory and manufacturing hurdle |
| Recombinant antibody fragment |
Technically possible, but development and validation burden is high |
| Small-molecule alternatives |
Not a direct substitute for Fab-mediated digoxin binding |
| Supportive care |
Used alongside antidote therapy, not a replacement in severe toxicity |
| Off-label use of related antibody products |
Limited and clinically non-equivalent |
The product has a stronger position in urgent care than in routine prescribing because clinicians cannot substitute supportive care for antibody neutralization in every severe exposure.
What formulation and manufacturing barriers protect the product?
The product is supplied as an injectable ovine Fab preparation. Important manufacturing controls include antibody generation, enzymatic fragmentation, purification, viral and adventitious-agent control, potency testing, sterility, aggregation control, stability and container-closure integrity.
Manufacturing risks
Source-animal controls
Ovine origin creates supply-chain requirements involving animal sourcing, immunization, disease control, traceability and consistency of antibody response.
Biological variability
Batch-to-batch variability can arise from differences in immunized animals, antibody titers and purification performance. Release testing must demonstrate adequate binding activity and acceptable purity.
Sterile injectable production
A sterile injectable antidote requires validated aseptic processing, sterilization strategy, particulate control and stability data. Manufacturing interruptions can have an immediate hospital impact.
Low-volume economics
The product’s limited annual demand can make dedicated manufacturing capacity expensive. A manufacturer may rely on portfolio production, long-term inventory planning and high unit pricing to support the business.
These barriers are not necessarily patent barriers. They are operational and regulatory barriers that can preserve market concentration after formal exclusivity expires.
What litigation and settlement agreements affect DigiFab?
No significant current patent litigation or Paragraph IV settlement involving DigiFab is identified in the cited public sources. The absence of public litigation is consistent with the product’s small market, limited generic pathway and difficult manufacturing profile.
The principal legal exposures are more likely to involve:
- Product liability after delayed or inadequate treatment.
- Manufacturing deviations and supply interruptions.
- Contractual disputes over distribution or hospital supply.
- Regulatory compliance involving biological-source materials.
- Commercial disputes arising from portfolio acquisitions or licensing arrangements.
No publicly documented settlement is cited here that would establish a scheduled generic or biosimilar launch date.
What licensing deals and ownership changes matter?
BTG’s acquisition by SERB Pharmaceuticals is the most relevant ownership event for the product’s commercial context. SERB completed its acquisition of BTG in 2020, bringing BTG’s specialty-pharmaceutical portfolio into a privately held company focused on critical-care and specialty medicines. [2]
The ownership change matters because DigiFab is better understood as a portfolio asset than as a standalone growth product. Its value may include:
- Recurring hospital demand.
- Emergency-medicine positioning.
- Manufacturing and regulatory know-how.
- Distribution relationships.
- Cross-selling with other critical-care products.
- Supply continuity in a market where hospitals value dependable access.
No material public licensing agreement is cited that creates a near-term competitive launch or changes the exclusivity analysis.
How does DigiFab compare with other antidote markets?
| Attribute |
DigiFab |
Naloxone |
N-acetylcysteine |
Digoxin immune Fab market |
| Primary use |
Severe digoxin or cardiac-glycoside toxicity |
Opioid overdose |
Acetaminophen toxicity |
Narrow, high-acuity antidote |
| Volume |
Low |
High |
Moderate to high |
Low |
| Use pattern |
Episodic emergency use |
Broad emergency and community use |
Emergency and inpatient use |
Hospital-stocked and event-driven |
| Product complexity |
Biological antibody fragment |
Small molecule |
Small molecule |
High |
| Generic competition |
Limited relative to common generics |
Substantial |
Substantial |
Limited |
| Pricing power |
Relatively high per treatment course |
Lower |
Lower |
Relatively high |
| Main commercial risk |
Low utilization and supply interruption |
Price competition |
Generic erosion |
Market concentration and replacement entry |
DigiFab has a less attractive volume profile than mass-market antidotes but a stronger scarcity premium. Its business is commercially defensible when supply is reliable and hospitals consider the product indispensable.
What generic launch risks exist for DigiFab?
The near-term generic launch risk appears low, but a long-term replacement-product risk remains.
Low near-term risk
- No identified approved biosimilar or direct generic.
- No identified Paragraph IV litigation.
- Difficult biological manufacturing.
- Small addressable market.
- Need for emergency-stock distribution.
- Clinical risk associated with an unfamiliar replacement product.
Medium- to long-term risk
- A manufacturer with existing ovine-antibody capabilities could enter.
- A new biologic could use modern analytical characterization to support approval.
- Hospitals could accept a lower-priced alternative if supply and clinical evidence are comparable.
- Public-health procurement could encourage a second source.
- A shortage could create commercial space for an entrant.
A successful entrant would likely compete first on supply assurance and price, not on incremental clinical differentiation.
How strong is the patent estate for digoxin immune Fab?
The patent estate appears weak as a standalone barrier, while the broader commercial moat is moderate.
| Factor |
Rating |
Rationale |
| Active composition patents |
Low |
Mature product and no clearly identified blocking patent |
| Regulatory exclusivity |
Low |
Original approval-era protections have expired |
| Manufacturing know-how |
Moderate to high |
Biological production and quality control are difficult |
| Brand and hospital familiarity |
Moderate |
Emergency clinicians value established products |
| Distribution position |
Moderate |
Hospital stocking and emergency supply relationships matter |
| Clinical substitution risk |
Low in severe toxicity |
Supportive care does not fully replace antibody neutralization |
| New-entrant risk |
Low near term |
Market size and manufacturing hurdles constrain entry |
| Long-term competitive durability |
Moderate |
Durable if supply remains reliable and pricing is accepted |
What is the geographic coverage and international opportunity?
DigiFab’s commercial opportunity is strongest in markets with:
- Established digoxin use.
- Centralized hospital procurement.
- Poison-control infrastructure.
- Capacity to fund high-cost emergency medicines.
- Regulatory pathways for biological antidotes.
International revenue can be constrained by country-specific registration requirements, limited local demand, import controls for animal-derived biologics and cold-chain or specialty-distribution requirements. Expansion into additional jurisdictions may increase addressable demand, but the market remains structurally narrow.
The product may have particular value in countries where oleander and other cardiac-glycoside poisonings occur. That opportunity is episodic and difficult to forecast. It can support strategic stocking agreements but does not create predictable chronic-treatment revenue.
Key Takeaways
- Digoxin immune Fab (ovine) is a mature, specialized biologic antidote marketed primarily as DigiFab.
- Its commercial market is small by patient volume but supports high per-case value because treatment is urgent and substitution is limited.
- Standalone product revenue, margin and unit data are not publicly disclosed.
- The product’s formal patent and exclusivity position appears weak, but manufacturing know-how, regulatory complexity and hospital stocking create practical barriers.
- No material Paragraph IV challenge, approved biosimilar or scheduled generic launch is identified.
- The most relevant corporate event is SERB Pharmaceuticals’ acquisition of BTG in 2020.
- Financial performance is likely driven by price, inventory replacement, supply reliability and geographic access rather than prescription growth.
- The principal long-term threat is a second biological supplier, not a conventional small-molecule generic.
FAQs About Digoxin Immune Fab (Ovine)
Is DigiFab still FDA approved?
Yes. DigiFab is an FDA-approved digoxin immune Fab product for potentially life-threatening or life-threatening digoxin toxicity. [1]
Is DigiFab a biosimilar?
No FDA-approved biosimilar or interchangeable product is identified for DigiFab in the cited sources.
Does DigiFab have an Orange Book patent listing?
Orange Book treatment is not the primary framework for this biological product. Biologic regulatory and patent information should be reviewed through FDA biologics resources and relevant patent databases.
Why is digoxin immune Fab expensive?
The product is a low-volume sterile biologic requiring ovine antibody production, purification, potency testing, inventory management and emergency hospital distribution. Those costs are spread across a small number of treated patients.
Can hospitals replace DigiFab with supportive care?
Supportive care may be used alongside antidote therapy, but it does not provide the same digoxin-binding mechanism as digoxin immune Fab in severe toxicity. Treatment decisions are clinical and depend on the patient’s condition and exposure.
References
- U.S. Food and Drug Administration. (2020). DigiFab (digoxin immune Fab [ovine]) prescribing information. FDA. https://www.accessdata.fda.gov
- SERB Pharmaceuticals. (2020). SERB completes acquisition of BTG plc. https://www.serb.com
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA. https://purplebooksearch.fda.gov
- U.S. Food and Drug Administration. (2024). Drugs@FDA database. FDA. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/